We are live on
!
Find out more
LC
Lindbrook Capital Portfolio holdings
AUM
$1.08B
1-Year Est. Return
10.14%
This Fund
S&P 500
This Quarter
Est. Return
+7.65%
1 Year Est. Return
+10.14%
3 Year Est. Return
+35.77%
5 Year Est. Return
+141.26%
10 Year Est. Return
–
AUM
$939M
AUM Growth
+$86.2M
(+10%)
Cap. Flow
+$29.6M
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
46.18%
Holding
2,925
New
150
Increased
988
Reduced
857
Closed
215
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Total International Stock ETF
VXUS
|
+$5.37M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.7M |
| 3 |
Vanguard Morningstar Total Stock Market ETF
VTI
|
+$2.54M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$2.12M |
| 5 |
NVIDIA
NVDA
|
+$1.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$6.88M |
| 2 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$4.62M |
| 3 |
Oaktree Specialty Lending
OCSL
|
+$825K |
| 4 |
MGI
MoneyGram International, Inc. New
MGI
|
+$627K |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$562K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.18% |
| 2 | Technology | 15.3% |
| 3 | Healthcare | 6.27% |
| 4 | Consumer Discretionary | 3.61% |
| 5 | Industrials | 3.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SEM
1426
DELISTED
Select Medical
SEM
| $10.6K | ﹤0.01% |
620
| – | – |
|
1427
Sylvamo
SLVM
$1.6B
| $10.6K | ﹤0.01% |
263
-42
| -14% | -$1.81K |
|
|
HAPN
1428
Happen Inc
HAPN
$2.24B
| $10.6K | ﹤0.01% |
+1,088
| New | +$8.74K |
|
1429
Murphy USA
MUSA
$10.2B
| $10.6K | ﹤0.01% |
34
+16
| +89% | +$4.48K |
|
1430
Trupanion
TRUP
$1.27B
| $10.6K | ﹤0.01% |
537
| – | – |
|
1431
State Street SPDR S&P Regional Banking ETF
KRE
$4.56B
| $10.5K | ﹤0.01% |
258
| – | – |
|
1432
Vicor
VICR
$9.63B
| $10.5K | ﹤0.01% |
195
+189
| +3,150% | +$9.33K |
|
1433
Universal Display
OLED
$4.16B
| $10.5K | ﹤0.01% |
73
-2
| -3% | -$287 |
|
1434
SentinelOne
S
$7.62B
| $10.5K | ﹤0.01% |
696
-166
| -19% | -$2.81K |
|
1435
Maravai LifeSciences
MRVI
$895M
| $10.5K | ﹤0.01% |
845
-89
| -10% | -$1.2K |
|
|
RC
1436
Ready Capital
RC
$333M
| $10.5K | ﹤0.01% |
+930
| New | +$9.82K |
|
|
EFC
1437
Ellington Financial
EFC
$1.69B
| $10.5K | ﹤0.01% |
758
| – | – |
|
1438
Arrowhead Research
ARWR
$12.5B
| $10.4K | ﹤0.01% |
293
+99
| +51% | +$3.41K |
|
1439
Organon & Co
OGN
$3.58B
| $10.4K | ﹤0.01% |
502
-436
| -46% | -$9.48K |
|
1440
National Health Investors
NHI
$3.59B
| $10.4K | ﹤0.01% |
199
+98
| +97% | +$5.05K |
|
1441
Qfin Holdings
QFIN
$1.59B
| $10.3K | ﹤0.01% |
597
-172
| -22% | -$2.89K |
|
1442
Tetra Tech
TTEK
$8.97B
| $10.3K | ﹤0.01% |
315
-20
| -6% | -$588 |
|
1443
Regal Rexnord
RRX
$11.5B
| $10.3K | ﹤0.01% |
67
+1
| +2% | +$136 |
|
1444
Robinhood
HOOD
$85B
| $10.3K | ﹤0.01% |
1,031
-187
| -15% | -$1.74K |
|
1445
HUB Group
HUBG
$2.9B
| $10.3K | ﹤0.01% |
256
+10
| +4% | +$387 |
|
1446
Hexcel
HXL
$7.63B
| $10.3K | ﹤0.01% |
135
+9
| +7% | +$641 |
|
1447
Crown Holdings
CCK
$13.1B
| $10.3K | ﹤0.01% |
118
+19
| +19% | +$1.56K |
|
1448
Great Southern Bancorp
GSBC
$873M
| $10.2K | ﹤0.01% |
202
-4
| -2% | -$204 |
|
1449
Ciena
CIEN
$54.9B
| $10.2K | ﹤0.01% |
241
-1
| -0.4% | -$46 |
|
|
EMFM
1450
DELISTED
Global X MSCI Next Emerging & Frontier ETF
EMFM
| $10.2K | ﹤0.01% |
560
| – | – |
|
Similar funds
SBIA
CHP
MW
TAM
SIA
CIG
CCM
WCF
Lindbrook Capital's Q2 2023 Portfolio in Review
As of Q2 2023, Lindbrook Capital held 2,925 positions worth $939M, up 10% from $853M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Lindbrook Capital deployed $29.6M of net new capital in Q2 2023, opening 150 new positions and adding to 988 existing holdings. Its largest new stake was UPAR Ultra Risk Parity ETF: 21,000 shares worth $291K.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $6.88M trimmed.
- Lindbrook Capital's largest Q2 2023 buy was UPAR Ultra Risk Parity ETF: 21,000 shares worth $291K.
- Lindbrook Capital added most to Vanguard Total International Stock ETF in Q2 2023, an estimated $5.37M increase.
- Lindbrook Capital's biggest Q2 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $6.88M.
- Lindbrook Capital fully exited MoneyGram International, Inc. New in Q2 2023, selling an estimated $627K.
- Lindbrook Capital's ten largest holdings make up 46% of its $939M portfolio in Q2 2023.
- Lindbrook Capital opened 150 new positions and closed 215 in Q2 2023.
- Lindbrook Capital's portfolio value rose 10% quarter-over-quarter to $939M.
Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.